Psilocybin Plus NMDA Modulators Reduce Hallucinations While Boosting Brain Plasticity
Combining psilocybin with D-serine or D-cycloserine dramatically reduced hallucinogenic effects while enhancing neuroplasticity markers in mice.
Summary
Israeli researchers found that combining psilocybin with NMDA receptor modulators (D-serine or D-cycloserine) dramatically reduced the hallucinogenic side effects of psilocybin while preserving or enhancing its neuroplasticity benefits. In mice, these combinations completely eliminated head-twitch responses (a measure of hallucinations) and reduced hyperactivity associated with psychosis models. Importantly, the combinations increased key brain plasticity proteins across multiple brain regions, suggesting the therapeutic benefits of psilocybin could be maintained while minimizing adverse effects that currently require supervised clinical settings.
Detailed Summary
This groundbreaking study from Hebrew University addresses a major limitation of psychedelic therapy: the need for costly supervised clinical settings due to hallucinogenic side effects. Researchers investigated whether combining psilocybin with NMDA receptor modulators could preserve therapeutic benefits while reducing adverse effects.
The team tested male ICR mice with psilocybin (4.4 mg/kg) alone or combined with D-serine (3000 mg/kg) or D-cycloserine (320 mg/kg). They measured head-twitch response (HTR) as a proxy for hallucinations, MK-801-induced hyperlocomotion as a model for antipsychotic effects, and neuroplasticity protein levels in four brain regions.
The results were striking: psilocybin alone significantly increased HTR (p<0.0001), but combining it with either D-serine or D-cycloserine completely eliminated this response, making it indistinguishable from vehicle control. This effect was dose-dependent and reproducible at lower doses. Similarly, both combinations significantly reduced MK-801-induced hyperactivity, suggesting antipsychotic properties.
Most importantly, the combinations enhanced neuroplasticity markers. Psilocybin plus D-serine increased GAP43 expression across all four brain regions and boosted overall synaptic protein expression in the hippocampus. Psilocybin plus D-cycloserine elevated PSD95 levels across all brain regions. These proteins are crucial for synapse formation and neural plasticity.
The findings suggest a potential paradigm shift in psychedelic medicine. By combining psilocybin with well-established, FDA-approved compounds like D-cycloserine (used for tuberculosis since the 1950s), researchers may have found a way to harness psilocybin's therapeutic neuroplasticity effects while eliminating the need for supervised clinical environments. This could dramatically expand access to psychedelic therapy for depression, PTSD, and other conditions.
Key Findings
- Psilocybin 4.4 mg/kg combined with D-serine 3000 mg/kg completely eliminated head-twitch response (p<0.0001 vs psilocybin alone)
- Psilocybin plus D-cycloserine 320 mg/kg reduced head-twitch response by 75% compared to psilocybin alone (p=0.0001)
- Both combinations significantly reduced MK-801-induced hyperlocomotion, modeling antipsychotic effects
- Psilocybin-D-serine combination enhanced GAP43 protein expression across all four brain regions examined
- Psilocybin-D-cycloserine combination elevated PSD95 levels across frontal cortex, hippocampus, amygdala, and striatum
- Effects were dose-dependent: lower doses (psilocybin 1.5 mg/kg + D-serine 1500 mg/kg) also completely eliminated head-twitch response
- D-cycloserine doses as low as 22.2 mg/kg showed dose-dependent reduction in hallucinogenic effects
Methodology
Controlled study using male ICR mice (30±2g) with separate cohorts for behavioral and neuroplasticity measurements. Head-twitch response measured via electromagnetic detection over 30 minutes. MK-801 hyperlocomotion assessed in open field for 60 minutes. Synaptic proteins (GAP43, PSD95, synaptophysin, SV2A) analyzed via Western blot 12 days post-treatment across four brain regions. Statistical analysis used ANOVA with Bonferroni/Tukey post-hoc tests.
Study Limitations
Study conducted only in male mice, limiting generalizability to humans and females. Neuroplasticity measurements were taken at a single timepoint (12 days), so duration of effects remains unclear. The study was funded by Negev Labs, though no specific conflicts of interest were disclosed. Long-term safety and efficacy of these combinations in humans requires clinical validation.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.